APC, a research and development company based in Ireland, has completed a €10 million investment, expanding its facilities at its headquarters in Cherrywood, Dublin, and resulting in 50 new research and development positions at the facility.

APC partners with the pharmaceutical and biotech industry to support the development of life- saving medicines. The company is currently working on more than 20 medicines for a variety of cancers, respiratory diseases, Alzheimer’s and HIV.

The company currently employs 120 people, the majority of which are chemical engineers, process and biopharmaceutical scientists. The new facility will bring the total sq.-ft. to 60,000 at the Cherrywood HQ, with staff numbers expected to increase by over 40% by the end of 2019.

Mark Barrett, chief executive officer of APC, said the investment represents APC’s continued expansion into new and emerging therapies and technologies such as viral, gene and cell therapies. “We are also delighted that the new facility with Bavarian Nordic will enforce our stated mission of accelerating the development of quality, life-changing medicines to patients.”